ArticleCancer cell2015
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.
Article in Cancer cell, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
116 citing papers in PubMed, 1 synthesis or guideline pooled it, 179 citations in OpenAlex.
- Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy.Advanced drug delivery reviews · 2020Pooled it
- Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026Review
- The application of antibody-based agents in cancer therapy based on their mechanisms of action.Fundamental research · 2025Review
- Tumor Integrin-Targeted Glucose Oxidase Enzyme Promotes ROS-Mediated Cell Death that Combines with Interferon Alpha Therapy for Tumor Control.Molecular cancer therapeutics · 2025Article
- Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming.Frontiers in immunology · 2025Article
- Protecting Against Postsurgery Oral Cancer Recurrence with an Implantable Hydrogel Vaccine for In Situ Photoimmunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Augmentation of Solid Tumor Immunotherapy With IL-12.The journal of gene medicine · 2024Review
- Distinct host preconditioning regimens differentially impact the antitumor potency of adoptively transferred Th17 cells.Journal for immunotherapy of cancer · 2024Article
- Engineering approaches for innate immune-mediated tumor microenvironment remodeling.Immuno-oncology technology · 2024Review
- CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes.Nature communications · 2024Article
- Immune cell networking in solid tumors: focus on macrophages and neutrophils.Frontiers in immunology · 2024Review
- Overcoming lung cancer immunotherapy resistance by combining nontoxic variants of IL-12 and IL-2.JCI insight · 2023Article
- Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses.Nature biomedical engineering · 2023Article
- IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25Nature cancer · 2023Article
- Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles.Communications biology · 2023Article
- Nanocarriers for cancer nano-immunotherapy.Drug delivery and translational research · 2023Review
- Anti-PD-1 and Extended Half-life IL2 Synergize for Treatment of Murine Glioblastoma Independent of Host MHC Class I Expression.Cancer immunology research · 2023Article
- Lipid-based nanoparticles for cancer immunotherapy.Medical review (2021) · 2023Review
- A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy.Nature biotechnology · 2023Article
- Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 1 country.
Funding
Abstract
Cancer immunotherapies under development have generally focused on either stimulating T cell immunity or driving antibody-directed effector functions of the innate immune system such as antibody-dependent cell-mediated cytotoxicity (ADCC). We find that a combination of an anti-tumor antigen antibody and an untargeted IL-2 fusion protein with delayed systemic clearance induces significant tumor control in aggressive isogenic tumor models via a concerted innate and adaptive response involving neutrophils, NK cells, macrophages, and CD8(+) T cells. This combination therapy induces an intratumoral "cytokine storm" and extensive lymphocyte infiltration. Adoptive transfer of anti-tumor T cells together with this combination therapy leads to robust cures of established tumors and development of immunological memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.